human
papillomaviru
hpv
infect
particularli
problemat
hiv
solid
organ
transplant
patient
compromis
celldepend
immun
produc
sever
progress
diseas
compar
healthi
individu
specif
treatment
chronic
hpv
infect
result
urgent
unmet
need
modal
safe
effect
immunocompromis
otherwis
normal
patient
recalcitr
diseas
dna
vaccin
attract
avoid
risk
administr
live
vector
immunocompromis
patient
induc
potent
hpvspecif
cytotox
cell
respons
develop
dna
vaccin
encod
calreticulin
crt
fuse
protein
genotyp
associ
approxim
vagin
vulvar
anal
penil
oropharyng
hpvassoci
cancer
major
cervic
cancer
administr
dna
vaccin
intramuscular
im
inject
follow
electropor
induc
significantli
greater
hpvspecif
immun
respons
compar
im
inject
alon
mix
alum
furthermor
dna
vaccin
via
electropor
mice
carri
intravagin
syngen
tumor
demonstr
potent
therapeut
effect
im
vaccin
alon
note
administr
dna
vaccin
im
inject
follow
electropor
elicit
potent
cell
respons
antitumor
effect
despit
celldeplet
although
antibodi
respons
detect
celldeplet
reduc
cell
respons
remain
suffici
prevent
subcutan
tumor
growth
elimin
circul
tumor
cell
model
metastat
cancer
thu
antibodi
respons
wherea
cell
help
enhanc
cell
immun
requir
taken
togeth
data
suggest
dna
vaccin
via
electropor
warrant
test
otherwis
healthi
patient
compromis
cell
immun
treat
anogenit
diseas
cancer
one
hundr
known
human
papillomavirus
hpv
dozen
high
risk
type
associ
cancer
oncogen
type
infect
genit
mucosa
sexual
transmit
oncogen
hpv
primari
etiolog
agent
cervic
cancer
also
known
caus
subset
head
neck
vagin
vulvar
anal
penil
cancer
problemat
type
caus
least
half
cervic
cancer
great
major
approxim
hpvassoci
cancer
anogenit
site
oral
caviti
hpvassoci
diseas
signific
problem
hiv
otherwis
immunocompromis
patient
less
abl
clear
hpv
infect
healthi
individu
hpvassoci
cancer
incid
significantli
elev
multipl
site
hiv
patient
notabl
cervic
cancer
design
hivassoci
malign
anal
cancer
predominantli
driven
addit
hiv
patient
frequent
acquir
multityp
infect
mani
infrequ
seen
healthi
individu
consequ
target
current
hpv
vaccin
furthermor
benign
hpv
diseas
also
sever
intract
hiv
solid
organ
transplant
patient
specif
treatment
chronic
hpv
infect
wart
typic
treat
limit
success
surgeri
ablat
via
cryotherapi
nonspecif
immun
modul
therefor
remain
urgent
need
therapi
effect
treat
chronic
oncogen
hpv
infect
particularli
associ
diseas
use
approach
safe
effect
even
immunocompromis
patient
one
potenti
strategi
treat
hpv
infect
diseas
immunocompromis
patient
dna
vaccin
dna
vaccin
elicit
cellmedi
andor
humor
immun
respons
consid
safe
even
immunocompromis
individu
contain
live
pathogen
although
intramuscular
im
dna
inject
low
effici
host
cell
transduct
encod
antigen
express
deliveri
greatli
enhanc
immedi
electropor
inject
site
previous
gener
variou
therapeut
hpv
dna
vaccin
encod
hpv
antigen
includ
variou
enhanc
strategi
target
antigen
endosomallysosom
compart
well
linkag
extracellular
domain
fmslike
tyrosin
kinas
transloc
domain
bacteri
toxin
particular
found
linkag
heat
shock
protein
calreticulin
crt
dna
vaccin
potent
enhanc
immun
respons
heterolog
antigen
inde
one
dna
vaccin
encod
crt
link
antigen
detox
advanc
clinic
trial
detox
dna
vaccin
current
test
phase
clinic
trial
patient
head
neck
cancer
trial
grade
cervic
intraepitheli
neoplasia
although
clinic
grade
detox
dna
vaccin
use
clinic
could
potenti
improv
fusion
addit
hpv
antigen
shown
cellmedi
immun
respons
hpv
antigen
associ
favor
clinic
outcom
may
immunodomin
patient
furthermor
humor
immun
respons
capsid
protein
shown
provid
broad
protect
infect
wide
spectrum
hpv
subtyp
anim
model
therefor
develop
prevent
therapeut
hpv
dna
vaccin
encod
crt
link
protein
crossprotect
effect
neutral
antibodi
potenti
prevent
unusu
hpv
type
multityp
hpv
infect
seen
hiv
popul
inde
previous
found
vaccin
dna
vaccin
capabl
gener
hpv
neutral
antibodi
well
control
tumor
preclin
model
contrast
patient
poorli
immunogen
mous
immun
dna
vaccin
express
fuse
crt
elicit
therapeut
respons
taken
togeth
dna
vaccin
promis
treatment
lesion
well
gener
panhpv
protect
effect
new
reinfect
howev
unclear
whether
vaccin
activ
patient
compromis
celldepend
immun
urgent
need
treatment
current
studi
test
immunogen
therapeut
effect
dna
vaccin
murin
model
anogenit
cancer
immunocompet
immunosuppress
set
vivo
electropor
enhanc
cellmedi
humor
hpv
antigenspecif
immun
respons
intramuscular
vaccin
dna
current
studi
first
sought
determin
ideal
rout
administr
dna
vaccin
mice
vaccin
three
time
twoweek
interv
dna
dose
either
without
alum
figur
vaccin
administ
intramuscularli
without
electropor
two
week
last
vaccin
splenocyt
serum
collect
treat
mice
analyz
cell
intracellular
cytokin
express
fcpsv
neutral
assay
respect
shown
figur
c
gener
im
administr
dna
vaccin
electropor
significantli
better
gener
hpv
antigenspecif
cell
compar
im
administr
dna
without
electropor
true
gener
consist
low
high
dose
dna
vaccin
group
furthermor
observ
alum
enhanc
gener
antigenspecif
cell
elicit
im
inject
dna
vaccin
electropor
figur
c
addit
shown
figur
dose
vaccin
dna
either
alum
electropor
gener
similar
level
hpvspecif
antibodi
dna
vaccin
administr
combin
alum
electropor
gener
minim
increas
antibodi
level
compar
vaccin
either
dna
alum
dna
electropor
overal
data
suggest
dna
vaccin
follow
electropor
gener
superior
hpvspecif
immun
respons
compar
im
inject
alon
alum
dna
vaccin
administ
intramuscularli
follow
electropor
gener
potent
antitumor
effect
mice
challeng
firefli
luciferaseexpress
tumor
cell
intravagin
week
old
femal
mice
micegroup
vaccin
either
dna
dna
formul
aluminum
phosphat
intramuscular
inject
follow
electropor
mice
boost
regimen
twice
interv
two
week
last
vaccin
serum
splenocyt
collect
summari
b
c
specif
cell
respons
analyz
intracellular
stain
splenocyt
stimul
peptid
presenc
golgiplug
overnight
cell
stain
antimous
follow
intracellular
data
acquir
facscalibur
analyz
cellquest
summari
neutral
antibodi
respons
shown
treatment
schedul
figur
mice
treat
dna
vaccin
im
administr
without
subsequ
electropor
day
tumor
challeng
shown
figur
im
administr
dna
vaccin
follow
electropor
significantli
reduc
intens
luminesc
indic
reduct
tumor
volum
compar
im
vaccin
without
electropor
furthermor
im
administr
dna
vaccin
follow
electropor
prolong
surviv
compar
im
vaccin
administr
without
electropor
figur
data
indic
electropor
significantli
enhanc
antitumor
effect
gener
dna
vaccin
next
examin
vaccin
administr
method
effect
gener
cell
mice
challeng
tumor
cell
intravagin
treat
begin
one
week
later
three
im
inject
threeday
interv
dna
vaccin
either
without
subsequ
electropor
splenocyt
tumor
infiltr
lymphocyt
harvest
day
last
vaccin
analyz
presenc
cell
shown
figur
im
inject
dna
vaccin
follow
electropor
gener
highest
percentag
cell
system
furthermor
mice
treat
dna
vaccin
administ
im
inject
follow
electropor
gener
significantli
greater
cell
among
vagin
tumor
infiltr
lymphocyt
compar
treat
im
inject
alon
figur
data
suggest
im
inject
follow
electropor
better
method
administr
dna
vaccin
compar
im
inject
alon
gener
antigenspecif
cellmedi
immun
respons
system
local
dna
vaccin
gener
potent
protect
antigenspecif
immun
respons
antitumor
effect
tumor
mice
found
vaccin
mice
detox
dna
elicit
potent
cell
respons
schemat
illustr
experi
mice
micegroup
challeng
intravagin
luc
cell
day
mice
either
left
untreat
immun
dna
vaccin
intramuscular
inject
follow
electropor
mice
boost
twice
interv
regimen
b
tumor
growth
follow
everi
week
bioluminesc
measur
photonsseccm
c
surviv
mice
monitor
everi
day
even
mice
deplet
cell
suggest
vaccin
may
still
activ
even
host
addit
file
figur
given
intent
also
target
examin
whether
dna
vaccin
effect
gener
hpv
antigenspecif
cellmedi
immun
respons
well
antitumor
effect
tumor
condit
cell
deplet
mice
deplet
cell
administr
antimous
antibodi
schedul
shown
figur
includ
prior
administr
dna
vaccin
effici
cell
deplet
verifi
peripher
blood
stain
follow
flow
cytometri
analysi
shown
figur
cell
complet
deplet
day
initi
antibodi
deplet
first
character
gener
hpv
antigenspecif
immun
respons
dna
vaccin
without
deplet
use
elisa
found
deplet
mice
treat
dna
vaccin
essenti
antibodi
respons
compar
nondeplet
mice
figur
suggest
success
ongo
cell
deplet
contrast
shown
figur
mice
treat
dna
vaccin
gener
significantli
greater
cell
among
total
cell
compar
mice
although
level
cell
lower
nondeplet
mice
nevertheless
dna
vaccin
confer
protect
subcutan
tumor
challeng
mice
nondeplet
mice
figur
data
indic
vaccin
dna
gener
potent
hpv
antigenspecif
cellmedi
immun
respons
translat
protect
antitumor
effect
absenc
cell
dna
vaccin
gener
potent
therapeut
antigenspecif
immun
respons
antitumor
effect
tumorbear
mice
next
test
whether
dna
vaccin
could
treat
tumorbear
mice
mice
mice
deplet
cell
prime
phase
challeng
tumor
cell
tail
vein
inject
mice
treat
dna
vaccin
three
time
oneweek
interv
im
inject
follow
electropor
figur
addit
dna
vaccin
mice
without
cell
deplet
includ
comparison
found
mice
treat
dna
vaccin
significantli
greater
percentag
cell
among
total
cell
compar
untreat
tumorbear
mice
figur
furthermor
number
cell
among
splenocyt
significantli
greater
mice
treat
dna
vaccin
compar
untreat
tumorbear
mice
figur
importantli
mice
treat
dna
vaccin
zero
lung
metastasi
nodul
nondeplet
mice
figur
addit
mice
treat
dna
vaccin
significantli
lower
lung
weight
compar
untreat
tumorbear
mice
without
deplet
figur
furthermor
dna
vaccin
mice
without
deplet
demonstr
statist
similar
lung
weight
figur
data
suggest
dna
vaccin
effect
treat
tumorbear
mice
despit
absenc
cell
current
studi
examin
protect
therapeut
effect
dna
vaccin
tumor
immunocompet
immunosuppress
mice
first
demonstr
administr
dna
vaccin
im
inject
follow
electropor
gener
greater
hpv
neutral
antibodi
titer
cellmedi
immun
respons
compar
im
inject
alon
although
use
alum
enhanc
hpv
neutral
antibodi
titer
effect
electropor
alon
combin
yield
clear
advantag
addit
use
alum
fail
enhanc
hpvspecif
cellular
immun
respons
elicit
im
vaccin
im
inject
week
old
femal
mice
micegroup
treat
antimous
delet
antibodi
clone
pb
via
intraperiton
inject
day
deplet
maintain
weekli
inject
deplet
antibodi
day
initi
deplet
mice
inject
cell
intraven
day
cell
inject
mice
vaccin
dna
vaccin
via
intramuscular
inject
follow
electropor
mice
boost
regimen
twice
interv
b
one
week
last
vaccin
pbmc
collect
cell
respons
analyz
peptid
load
b
tetram
stain
follow
flow
cytometri
analysi
c
day
last
vaccin
splenocyt
harvest
detect
cell
respons
analyz
intracellular
stain
diagram
number
cell
metastasi
nodul
weight
lung
e
dna
vaccin
follow
electropor
elicit
potent
cell
respons
therapeut
antitumor
effect
tumorbear
mice
compar
im
inject
without
electropor
respons
effect
target
tumor
vagin
tract
notabl
also
observ
potent
cellmedi
immun
respons
antitumor
effect
tumorbear
mice
taken
togeth
data
suggest
dna
vaccin
may
appropri
use
immunocompromis
patient
includ
hiv
patient
control
cancer
observ
mice
vaccin
dna
vaccin
capabl
gener
potent
hpv
antigenspecif
cellmedi
immun
respons
absenc
cell
previous
shown
dna
vaccin
encod
crt
link
target
antigen
capabl
gener
high
level
antigenspecif
cell
respons
well
signific
antitumor
immun
crt
heat
shock
protein
associ
peptid
deliv
er
well
mhc
class
microglobulin
molecul
aid
antigen
present
furthermor
crt
shown
bind
also
known
macroglobulin
receptor
low
densiti
lipoproteinrel
protein
cell
surfac
receptor
antigen
present
cell
thu
crt
may
abl
deliv
link
antigen
dendrit
cell
specif
bind
facilit
cross
prime
activ
furthermor
crt
shown
activ
dendrit
cell
dc
critic
safeti
featur
dna
vaccin
contain
mutat
detox
version
oncogen
essenti
clinic
translat
dna
vaccin
previous
shown
mutat
posit
andor
disrupt
rb
bind
site
thu
allevi
concern
oncogen
mutat
posit
destroy
singl
zinc
finger
construct
use
ongo
clinic
studi
addit
mutat
posit
shown
destroy
sever
key
oncogen
function
includ
abil
bind
prevent
detox
protein
immort
human
epitheli
cell
includ
delet
pdz
proteinbind
domain
cterminu
also
critic
transform
dna
construct
use
current
studi
includ
gene
contain
mutat
describ
thu
minim
safeti
concern
clinic
translat
clinic
set
dna
vaccin
deliv
varieti
method
includ
particlemedi
intraderm
deliveri
gene
gun
intralesion
inject
intramuscular
inject
intramuscular
inject
follow
electropor
gene
gun
enabl
deliv
dna
directli
transfect
keratinocyt
epiderm
langerhan
cell
immatur
dc
stimul
dc
matur
migrat
local
lymphoid
tissu
dc
prime
cell
hpv
antigenspecif
immun
respons
dna
vaccin
administr
electropor
increas
number
hpv
dnatransfect
cell
enhanc
magnitud
gene
express
requir
less
time
reach
maxim
immun
respons
compar
convent
intramuscular
vaccin
inject
use
electropor
devic
may
even
import
nonhuman
primat
human
mice
recent
report
clinic
trial
indic
deliveri
nake
dna
vaccin
electropor
capabl
gener
potent
cellular
well
humor
immun
respons
encod
hpv
antigen
addit
detox
dna
vaccin
administ
im
inject
electropor
test
head
neck
cancer
patient
well
via
intracerv
inject
gene
gun
like
devic
pmed
current
studi
suggest
potenti
dna
vaccin
treat
infect
diseas
hivand
hiv
patient
hiv
patient
particular
need
prevent
therapeut
hpv
vaccin
suscept
hpv
infect
often
frequent
multityp
infect
includ
uncommon
hpv
subtyp
furthermor
hiv
patient
exhibit
sever
progress
hpv
infect
compar
healthi
individu
dna
vaccin
potenti
fulfil
urgent
need
safe
effect
absenc
cell
elicit
potent
cellmedi
immun
respons
therapeut
antitumor
effect
murin
studi
week
old
femal
mice
purchas
nation
cancer
institut
frederick
md
mice
hous
john
hopkin
univers
school
medicin
cancer
center
anim
facil
specificpathogen
free
condit
procedur
perform
accord
approv
protocol
accord
recommend
proper
use
care
laboratori
anim
b
restrict
peptid
rahynivtf
b
restrict
peptid
ydfafrdl
synthes
macromolecular
resourc
denver
co
puriti
fitcconjug
antimous
clone
fitc
pe
apcconjug
antimous
clone
fitcconjug
antimous
clone
antibodi
purchas
bd
pharmingen
bd
pharmingen
san
diego
ca
peconjug
antimous
clone
antibodi
purchas
biolegend
san
diego
ca
peconjug
peptid
rahynivtf
load
b
tetram
obtain
nation
institut
allergi
infecti
diseas
tetram
facil
atlanta
ga
medroxyprogesteron
acet
purchas
greenston
llc
peapack
nj
purchas
reviv
person
product
compani
madison
nj
cell
gener
previous
describ
cell
establish
transduc
cell
luciferas
cell
maintain
rpmi
medium
supplement
mm
glutamin
mm
sodium
pyruv
penicillin
streptomycin
fetal
bovin
serum
fb
creation
lovot
describ
cultur
dmem
medium
contain
mm
glutamin
mm
sodium
pyruv
penicillin
streptomycin
fb
dna
vaccin
use
studi
construct
follow
briefli
contain
human
calreticulin
crt
three
mutat
two
mutat
delet
clone
human
crt
isol
sal
iecori
codon
modifi
synthes
genescript
piscataway
nj
cut
ecoribamhi
digest
human
crt
clone
vector
digest
salbamhi
mutat
delet
sequenc
detail
addit
file
figur
dna
vaccin
administ
mice
via
intramuscular
im
inject
flank
without
subsequ
electropor
ichor
electropor
deliveri
system
td
ichor
medic
system
inc
san
diego
ca
describ
previous
aluminum
phosphat
use
dna
mix
aluminum
phosphat
final
volum
dnaaluminum
phosphat
mixtur
use
within
half
hour
prepar
vaccin
schedul
requir
booster
vaccin
contralater
leg
use
vaccin
subsequ
vaccin
use
altern
hind
leg
deplet
cell
mice
inject
deplet
antimous
antibodi
clone
day
via
intraperiton
inject
deplet
maintain
experi
inject
antibodi
per
week
success
deplet
confirm
stain
peripher
blood
cell
antimous
antibodi
recogn
differ
epitop
deplet
antibodi
product
furincleav
pseudovirus
fcpsv
describ
elsewher
briefli
fcpsv
produc
follow
standard
psv
product
protocol
follow
modif
instead
cell
cell
use
ammonium
sulfat
exclud
matur
buffer
concentr
cacl
matur
buffer
increas
mm
matur
time
increas
hour
hour
detail
vitro
hpv
pseudoviru
neutral
assay
describ
elsewher
briefli
lovot
cell
plate
tissu
cultur
plate
next
day
mous
serum
serial
dilut
mix
fcpsv
contain
luciferas
incub
hour
ad
cell
plate
incub
hour
luciferas
activ
analyz
reduct
luciferas
activ
consid
posit
neutral
antibodi
respons
determin
enzymelink
immunosorb
assay
elisa
describ
previous
optic
densiti
od
valu
read
xmark
micropl
spectrophotomet
biorad
hercul
ca
elisa
reader
nm
singl
splenocyt
suspens
prepar
mesh
spleen
lyse
red
blood
cell
prepar
singl
cell
vagin
tumor
tumor
surgic
resect
steril
condit
place
rpmi
medium
contain
penicillin
streptomycin
ice
wash
phosphatebuff
salin
pb
solid
tumor
minc
piec
incub
serumfre
rpmi
medium
contain
collagenas
dnase
roch
indianapoli
penicillin
streptomycin
incub
period
agit
cell
filter
nylon
filter
mesh
remov
undigest
tissu
fragment
result
singl
tumor
cell
suspens
wash
twice
hank
buffer
salt
solut
hbss
g
min
viabl
cell
determin
use
trypan
blue
dye
exclus
tetram
stain
splenocyt
tumor
infiltr
lymphocyt
stain
purifi
antimous
fc
block
bd
pharmingen
san
diego
ca
first
stain
antimous
peconjug
peptid
rahynivtf
load
b
tetram
wash
cell
stain
prior
flow
cytometri
analysi
exclud
dead
cell
cell
acquir
facscalibur
analyz
cellquest
bd
bioscienc
mountain
view
ca
flowjo
softwar
tree
star
ashland
detect
cell
respons
intracellular
stain
splenocyt
stimul
either
peptid
presenc
golgiplug
bd
pharmingen
san
diego
ca
overnight
stimul
splenocyt
wash
facscan
buffer
stain
peconjug
monoclon
rat
antimous
cell
subject
intracellular
cytokin
stain
use
cytofixcytoperm
kit
accord
manufactur
instruct
bd
pharmingen
san
diego
ca
intracellular
stain
fitcconjug
rat
antimous
flow
cytometri
analysi
perform
use
facscalibur
cellquest
softwar
mice
deplet
cell
mice
inject
deplet
antimous
antibodi
clone
day
via
intraperiton
inject
describ
mice
vaccin
dna
im
inject
follow
electropor
three
time
twoweek
interv
day
last
vaccin
mice
inject
cell
subcutan
tumor
growth
monitor
palpat
twice
week
test
whether
dna
vaccineinduc
cell
respons
could
cure
exist
tumor
orthotop
vagin
tumor
model
use
deplet
perform
describ
briefli
femal
mice
treat
mg
mous
medroxyprogesteron
acet
via
subcutan
inject
day
later
mice
treat
intravagin
overnight
wash
cell
instil
intravagin
caviti
seven
day
tumor
challeng
mice
vaccin
dna
im
inject
follow
electropor
three
time
threeday
interv
tumor
growth
monitor
luminesc
imag
indic
time
point
vivo
tumor
treatment
experi
hematolog
spread
model
cell
deplet
mice
inject
cell
intraven
via
tail
vein
day
later
mice
vaccin
dna
vaccin
via
im
administr
follow
electropor
boost
twice
regimen
oneweek
interv
day
cell
challeng
mice
sacrif
splenocyt
prepar
detect
cell
respons
lung
harvest
examin
tumor
growth
data
express
mean
standard
deviat
sd
comparison
individu
data
point
analyz
student
test
data
tumor
treatment
experi
evalu
analysi
varianc
anova
surviv
distribut
mice
differ
group
compar
kaplanmei
curv
use
longrank
test
p
valu
less
consid
signific
addit
file
figur
peptid
load
mhc
class
tetram
stain
character
frequenc
cell
dna
vaccin
mice
without
deplet
mice
per
group
vaccin
dna
intraderm
via
gene
gun
twice
interv
use
method
similar
describ
previous
mice
vaccin
empti
vector
includ
control
one
group
dna
vaccin
mice
deplet
cell
day
dna
vaccin
continu
deplet
cell
twice
week
mous
monoclon
antibodi
use
method
describ
previous
complet
cell
deplet
confirm
flow
cytometri
analysi
day
last
dna
vaccin
spleen
vaccin
mice
harvest
character
presenc
cell
use
peptid
aa
load
b
tetram
stain
stain
follow
flow
cytometri
analysi
richard
roden
inventor
patent
licens
shantha
biotechn
ltd
glaxosmithklin
paxvax
inc
acambi
inc
receiv
research
fund
sanofi
pasteur
glaxosmithklin
richard
roden
